Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)
Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma
Sponsor: Merck Sharp & Dohme LLC
This observational or N/A phase trial investigates Lymphoma, T-Cell, Cutaneous and is currently ongoing. Merck Sharp & Dohme LLC leads this study, which shows 11 recorded versions since 2026 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Sep 2022 — Jul 2024 [monthly]
No Longer Available
-
Jun 2022 — Sep 2022 [monthly]
No Longer Available
-
Jan 2021 — Jun 2022 [monthly]
No Longer Available
▶ Show 6 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
No Longer Available
-
Jun 2018 — Sep 2019 [monthly]
No Longer Available
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
-
Jun 2017 — Apr 2018 [monthly]
No Longer Available NA
Phase: PHASE3 → NA
-
Feb 2017 — Jun 2017 [monthly]
No Longer Available PHASE3
-
Jan 2017 — Feb 2017 [monthly]
No Longer Available PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.